Finance

Beta
Lists
002019:SHE
Yifan Pharmaceutical Co Ltd
CNÂ¥10.11
-2.13%
(-0.22) 1D
Jun 3, 3:04:30 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 002019...
Open
CNÂ¥10.33
High
CNÂ¥10.33
Low
CNÂ¥10.07
Mkt. cap
12.77B
Avg. vol.
12.67M
Volume
8.12M
Dividend
0.99%
Quarterly dividend
CNÂ¥0.03
Ex-dividend date
May 29, 2026
P/E ratio
34.49
52-wk high
CNÂ¥16.66
52-wk low
CNÂ¥10.07
EPS
CNÂ¥0.29
Shares outstanding
1.22B
No. of employees
4K
Open
CNÂ¥10.33
High
CNÂ¥10.33
Low
CNÂ¥10.07
Mkt. cap
12.77B
Avg. vol.
12.67M
Volume
8.12M
Dividend
0.99%
Quarterly dividend
CNÂ¥0.03
Ex-dividend date
May 29, 2026
P/E ratio
34.49
52-wk high
CNÂ¥16.66
52-wk low
CNÂ¥10.07
EPS
CNÂ¥0.29
Shares outstanding
1.22B
No. of employees
4K
News stories
From sources across the web
About Yifan Pharmaceutical Co Ltd
CEO-
Employees4.18K
Founded1994
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
1.31B
1.29B
1.21B
1.26B
Cost of goods sold
652.18M
683.41M
709.78M
680.09M
Cost of revenue
652.18M
683.41M
709.78M
680.09M
Research and development expenses
55.12M
73.24M
99.51M
54.37M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
400.70M
394.37M
380.61M
352.15M
Operating expense
466.37M
414.49M
557.81M
426.93M
Total operating expenses
1.12B
1.10B
1.27B
1.11B
Operating income
189.94M
189.70M
-57.35M
148.49M
Other non operating income
-5.25M
4.02M
-9.55M
-9.25M
EBT including unusual items
187.64M
90.49M
-11.11M
120.86M
EBT excluding unusual items
182.29M
171.87M
-75.15M
130.13M
Income tax expense
41.71M
14.39M
-24.31M
25.15M
Effective tax rate
22.23%
15.91%
218.84%
20.81%
Other operating expenses
7.59M
-60.21M
83.25M
11.12M
Net income
150.49M
84.14M
14.23M
106.83M
Net profit margin
11.50%
6.53%
1.18%
8.51%
Earnings per share
-
-
-
-
Interest and investment income
2.30M
2.44M
4.17M
2.64M
Interest expense
-12.45M
-16.54M
-10.67M
-11.75M
Net interest expenses
-10.15M
-14.10M
-6.51M
-9.11M
Depreciation and amortization charges
-
-
-
-
EBITDA
276.02M
268.85M
25.25M
231.09M
Gain or loss from assets sale
-3.86M
3.86M
-12.70M
-
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more